TRENDS IN PHARMACOLOGICAL SCIENCES **REFERENCE EDITION**

Volume 13 **1992**

CONTENTS

JANUARY

Meeting Report
Nitric oxide takes centre-stage with newly defined roles, *Thérèse McCall and Patrick Vallance* 1

Current Awareness
Cloning of the H_1 histamine receptor, *H. Timmerman* 6
Dopamine receptors in the caudate nucleus and memory processes, *Ivan Izquierdo* 7
A small K^+ channel looms large, *Louis H. Philipson and Richard J. Miller* 8

News
Will the real NMDA receptor please stand up? *Eric Barnard* 11

Letters
Ca^{2+} influx following receptor activation, *Javier García-Sancho, Javier Alvarez, Mayte Montero and Carlos Villalobos* 12
Mechanism of tetanus toxin in neuronal cell death, *John G. R. Jefferys* 13
Bagetta *et al.* reply, *G. Bagetta, G. Nisticò and N. G. Bowery* 14

This and That: the essential pharmacology of herbs and spices, *B. Max* 15

Comment
Questions about inhaled β_2-adrenoceptor agonists in asthma, *Peter J. Barnes and K. Fan Chung* 20

Viewpoint
Sickness behavior as a new target for drug development, *Stephen Kent, Rose-Marie Bluthé, Keith W. Kelley and Robert Dantzer* 24

Reviews
Pharmacological strategies in CNS trauma, *Alan I. Faden and Steven Salzman* 29
The role of the amygdala in fear-potentiated startle: implications for animal models of anxiety, *Michael Davis* 35

Books
Electrophysiology and Microinjection (Methods in Neurosciences, Vol. 4), *edited by P. Michael Conn* 41
Clinical Textbook of Addictive Disorders, *edited by Richard J. Frances and Sheldon I. Miller* 42
Principles of Pharmacology: A Tropical Approach, *by D. T. Okpako* 42
Defeating Pain. The War Against a Silent Epidemic, *by P. D. Wall and M. Jones* 43

FEBRUARY

Meeting Report
Lipocortin-1 exhibits novel actions, providing clinical opportunities, *Nancy J. Rothwell and Rod Flower* 45

Current Awareness
Nucleoside diphosphate kinases as potential new targets for control of development and cancer, *M. L. Lacombe and K. H. Jakobs* 46
Domains of muscarinic acetylcholine receptors that confer specificity of G protein-coupling, *Tom I. Bonner* 48

Current Techniques
Low-frequency components of cardiovascular variabilities as markers of sympathetic modulation, *Massimo Pagani, Ornella Rimoldi and Alberto Malliani* 50

Letters
Deviations from receptor theory? *Paul Leff, Iain G. Dougall and Diane Harper* 54

Special Feature
Nikolai Vasilyevich Lazarev, toxicologist and pharmacologist, comes in from the cold, *Robert L. Lipnick and Vladimir A. Filov* 56

Reviews
Molecular biology of dopamine receptors, *David R. Sibley and Frederick J. Monsma, Jr* 61
5-HT and alcohol abuse, *Edward M. Sellers, Guy A. Higgins and Mark B. Sobell* 69
Multiple benzodiazepine receptors: no reason for anxiety, *Adam Doble and Ian L. Martin* 76

Books
Antihormones in Health and Disease, *edited by M. K. Agarwal* 82
Vitamin C and Cancer: Medicine or Politics? *by Evelleen Richards* 82

MARCH

Meeting Report
A proposal for the classification of sigma binding sites, *Rémi Quirion, Wayne D. Bowen, Yossef Itzhak, Jean Louis Junien, José M. Musacchio, Richard B. Rothman, Tsung-Ping Su, S. William Tam and Duncan P. Taylor* 85

Current Awareness
Pharmacology and electrophysiology of ATP-activated ion channels, *Bruce P. Bean* 87
Myocardial preconditioning as the heart's self-protecting response against the consequences of ischaemia, *Cherry L. Wainwright* 90
Signal transduction from the extracellular matrix: the integrin–tyrosine kinase connection, *L. Kornberg and R. L. Juliano* 93

Current Techniques
Functional expression of receptors in microorganisms, *A. Donny Strosberg and Stefano Marullo* 95

This and That: creatine's superfluous methyl and the shadowed art of Cimabue, *B. Max* 99

Letters
RDC1 may not be VIP receptor, *Shigekazu Nagata, Takeshi Ishihara, Patrick Robberecht, Frederick Libert, Marc Parmentier, Jean Christophe and Gilbert Vassart* 102

Reviews
Molecular characterization of endothelin receptors, *Takeshi Sakurai, Masashi Yanagisawa and Tomoh Masaki* 103
Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities, *Sam Gandy and Paul Greengard* 108
The influence of endocardial endothelium on myocardial contraction, *Jerry A. Smith, Ajay M. Shah, Steve Fort and Malcolm J. Lewis* 113
Developments in the drug treatment of schizophrenia, *Gavin P. Reynolds* 116
Mapping determinants of the substrate selectivities of P450 enzymes by site-directed mutagenesis, *Eric F. Johnson* 122

Books
Neuropharmacology of Ethanol, New Approaches, *edited by Roger E. Meyer, George F. Koob, Michael J. Lewis and Steven M. Paul* 126
A Textbook of Drug Design and Development, *edited by Povl Krogsgaard-Larsen and Hans Bundgaard* 127

Software Review
Foundations of Pharmacology, *by R. B. Barlow* 128

Erratum
Multiple benzodiazepine receptors: no reason for anxiety, *by Adam Doble and Ian L. Martin* 86

APRIL

Current Awareness
Pathogenesis of NSAID gastropathy: are neutrophils the culprits? *John L. Wallace and D. Neil Granger* 129
Alzheimer's disease: pathology to potential treatments? *M. Claire Royston, Nancy J. Rothwell and Gareth W. Roberts* 131
Mechanism of action of taxol, *Susan Band Horwitz* 134

This and That: sequential theories for stomach cancer and the multiple applications of isotopic ratios, *B. Max* 136

Reviews
The 5-HT_4 receptor: a place in the sun, *Joël Bockaert, John R. Fozard, Aline Dumuis and David E. Clarke* 141
Therapeutic potential of cytokine manipulation, *Brian Henderson and Simon Blake* 145
A subfamily of 5-HT_{1D} receptor genes, *Paul R. Hartig, Theresa A. Branchek and Richard L. Weinshank* 152
Of mice and flies: commonalities among 5-HT receptors, *René Hen* 160

Books
Medicine and Mental Illness, *by M. E. Lickey and B. Gordon* 166
Neuropeptide Technology: Gene Expression and Neuropeptide Receptors (Methods in Neurosciences, Volume 5), *edited by P. Michael Conn* 166
A Social History of the Minor Tranquilizers: The Quest for Small Comfort in the Age of Anxiety, *by Mickey C. Smith* 167

Erratum
Developments in the drug treatment of schizophrenia, *by Gavin P. Reynolds* 140

MAY

Neurobiological perspectives on drugs of abuse, *Alison Abbott* 169

Reviews
Drugs of abuse: behavioural principles, methods and terms, *Ian Stolerman* 170
Drugs of abuse: anatomy, pharmacology and function of reward pathways, *George F. Koob* 177
Neurobiology of opiate abuse, *Gaetano Di Chiara and R. Alan North* 185
Neurobiology of cocaine abuse, *William L. Woolverton and Kenneth M. Johnson* 193
Neurobiology of marijuana abuse, *Mary E. Abood and Billy R. Martin* 201
Neurobiology of alcohol abuse, *Herman H. Samson and R. Adron Harris* 206
Genetic approaches to drug dependence, *John C. Crabbe and John K. Belknap* 212

Erratum
Developments in the drug treatment of schizophrenia, *by Gavin P. Reynolds* 184

JUNE

The three eras of research in experimental toxicology, *G. Zbinden* 221
Welcome to IUTOX, *P. Preziosi* 222

Current Awareness
Metabolic polymorphisms affecting activation of toxic and mutagenic arylamines, *Karl Walter Bock* 223
Cytokines and eicosanoids in cancer drug toxicity, *P. Preziosi, L. Parente and P. Navarra* 226
Anthranoid laxatives and colorectal cancer, *Claus-Peter Siegers* 229

Letters
Active enantiomers may cause adverse effects in asthma, *I. D. Chapman, K. H. Buchheit, P. Manley and J. Morley* 231
Endogenous bacterial receptors should cause anxiety, *Sarah Lummis* 232

Comment
Scientific discourse, in public, *Alastair Hay* 233

Reviews
Nerve membrane Na^+ channels as targets of insecticides, *Toshio Narahashi* 236
The dioxin and peroxisome proliferator-activated receptors: nuclear receptors in search of endogenous ligands, *Lorenz Poellinger, Martin Göttlicher and Jan-Åke Gustafsson* 241
Cell death by apoptosis and its protective role against disease, *Wilfried Bursch, Franziska Oberhammer and Rolf Schulte-Hermann* 245
Nuclear receptors and chemical carcinogenesis, *Stephen Green* 251
Receptor sites for Ca^{2+} channel antagonists, *William A. Catterall and Jörg Striessnig* 256

Erratum
Sequential theories for stomach cancer and the multiple applications of isotopic ratios, *by B. Max* 232

JULY

Current Awareness
Cardiac α_1-adrenoceptors mediate positive inotropy via myofibrillar sensitization, *M. Pucéat, A. Terzic, O. Clément, F. Scamps, S. M. Vogel and G. Vassort* 263
Nonpeptide antagonists herald new era in tachykinin research, *K. J. Watling* 266
K^+ channel openers and 'natural' cardioprotection, *Denis Escande and Icilio Cavero* 269

Obituary
Albrecht Fleckenstein (1917–1992), *David J. Triggle* 265

This and That: hair pigments, the hypoxic basis of life and the Virgilian journey of the spermatozoon, *B. Max* 272

Reviews
Pharmacological prospects for α_2-adrenoceptor antagonist therapy, *Michel Berlan, Jean-Louis Montastruc and Max Lafontan* 277
Use of *in vivo* apparent pA_2 analysis in assessment of opioid abuse liability, *J. H. Woods, G. Winger and C. P. France* 282
Cytokines and neuropathology, *Maria Cristina Morganti-Kossmann, Thomas Kossmann and Sharon M. Wahl* 286
Glutamate receptor channels: novel properties and new clones, *Bernd Sommer and Peter H. Seeburg* 291

Books
The Beta-Adrenergic Receptors, *edited by John P. Perkins* and β-Adrenoceptors: Molecular Biology, Biochemistry and Pharmacology (Progress in Basic and Clinical Pharmacology, Vol. 7), *edited by Robert R. Ruffolo, Jr* 296
Excitation–Contraction Coupling and Cardiac Contractile Force, *by Donald M. Bers* 297

Software Review
ORIGIN Versions 1.1 and 2.0, *MicroCal* 298

AUGUST

Current Awareness
New mutants to explore nicotinic receptor functions, *Jean-Pierre Changeux, Anne Devillers-Thiéry, Jean-Luc Galzi and Daniel Bertrand* 299
Pharmacological effects of drug conjugates: is morphine 6-glucuronide an exception? *Gerard J. Mulder* 302
Ca^{2+}-induced Ca^{2+} release and its modulation by cyclic ADP-ribose, *Antony Galione* 304

Viewpoint
Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine, *Michael A. Moskowitz* 307

Reviews
Galanin and galanin antagonists: molecular and biochemical perspectives, *Tamas Bartfai, Gilberto Fisone and Ülo Langel* 312
New insights into activation of the steroid hormone receptor superfamily, *Ronan F. Power, Orla M. Conneely and Bert W. O'Malley* 318
Designing therapeutically effective 5-lipoxygenase inhibitors, *R. M. McMillan and E. R. H. Walker* 323
The genetic basis of malignant hyperthermia, *David H. MacLennan* 330

Books
Gingko biloba Extract (EGb 761): Pharmacological Activities and Clinical Applications, *by F. V. DeFeudis* 334
Perturbing the Organism: The Biology of Stressful Experience, *by Herbert Weiner* 335

SEPTEMBER

Meeting Report
5-HT: on the psychiatrist's couch, *Mike Briley and David Grahame-Smith* 337

Current Awareness
Muscarinic receptor-mediated stimulation of adenylyl cyclase, *Jesse Baumgold* 339

This and That: an artefactual alkaloid and its peptide analogs, *B. Max* 341

Reviews
Human cytochromes P450: problems and prospects, *Frank J. Gonzalez* 346
Block and modulation of cardiac Na^+ channels by antiarrhythmic drugs, neurotransmitters and hormones, *Augustus O. Grant and David J. Wendt* 352
Structural basis of voltage-gated K^+ channel pharmacology, *Olaf Pongs* 359
Angiotensin receptor subtypes in the brain, *U. Muscha Steckelings, Serge P. Bottari and Thomas Unger* 365

Books
New editions 368

OCTOBER

Meeting Report
Keeping an eye on the I site: imidazoline-preferring receptors, *Martin C. Michel and Paul Ernsberger* 369

News
BPS 150th anniversary, *J. F. Mitchell* 370

Current Awareness
Cell volume and hormone action, *Dieter Häussinger and Florian Lang* 371
Amiloride: a molecular probe for mechanosensitive channels, *Owen P. Hamill, John W. Lane and Don W. McBride Jr* 373

Principles
Reverse intrinsic activity of antagonists on G protein-coupled receptors, *Wolfgang Schütz and Michael Freissmuth* 376

Viewpoint
Direct regulation of cardiac Ca^{2+} channels by G proteins: neither proven nor necessary, *H. Criss Hartzell and Rodolphe Fischmeister* 380

Reviews
Neuroendocrine actions of endothelins, *Stanko S. Stojilković and Kevin J. Catt* 385
Recent advances in the electrophysiological characterization of 5-HT_3 receptors, *John A. Peters, Hilary M. Malone and Jeremy J. Lambert* 391

Books
The Billion-Dollar Battle: Merck v Glaxo, *by Matthew Lynn* 397
The Airway Epithelium: Physiology, Pathophysiology and Pharmacology, *edited by S. G. Farmer and D. W. P. Hay* 398

NOVEMBER

Meeting Report
Dopamine: From Cinderella to Holy Grail, *Ann Mills* 399

Current Awareness
Regulation of brain neurotrophin expression by physiological activity, *Christine M. Gall* 401

Reviews
Membrane ion channels of endothelial cells, *Patricia A. Revest and N. Joan Abbott* 404
The fall and rise of neuronal α-bungarotoxin binding proteins, *Paul B. S. Clarke* 407
Development of GPIIb/IIIa antagonists as antithrombotic drugs, *Andrew J. Nichols, Robert R. Ruffolo, Jr, William F. Huffman, George Poste and James Samanen* 413

Books
Aromatic Heterocyclic Chemistry, *D. T. Davies* 417
Monitoring Neuronal Activity: A Practical Approach, *J. A. Stamford* 418
Autonomic Neuroeffector Mechanisms, *edited by G. Burnstock and C. H. V. Hoyle* 418
Handbook of PAF and PAF antagonists, *edited by P. Braquet* 419
Endocrine Toxicology, *edited by C. K. Atterwili and J. D. Flack* 419
New Edition 420

DECEMBER

Meeting Report
Transporter explosion: update on uptake, *George R. Uhl and Paul R. Hartig* 421

Current Awareness
Development of the cytokine inducer romurtide: experimental studies and clinical application, *Ichiro Azuma* 425

Letters
Reinforcing drug seeking, *Gaetano Di Chiara* 428
Reply, *Ian Stolerman* 429
Unravelling the paradox, *D. Colquhoun* 429
Reply, *R. A. Harris and H. H. Samson* 430

Principles
How to estimate the total receptor concentration when the specific radioactivity of the ligand is unknown, *Stéphane Swillens* 430

Reviews
The role of individual human cytochromes P450 in drug metabolism and clinical response, *Suzanne Cholerton, Ann K. Daly and Jeffrey R. Idle* 434
Neuroprotective role of adenosine in cerebral ischaemia, *Karl A. Rudolphi, Peter Schubert, Fiona E. Parkinson and Bertil B. Fredholm* 439
$GABA_A$ receptors: ligand-gated Cl^- ion channels modulated by multiple drug-binding sites, *Werner Sieghart* 446

Books
Receptor–Ligand Interactions, A Practical Approach, *J. Wharton* 451
Progress in Medicinal Chemistry. Volume 29, *P. D. Leeson* 451
Brain Function and Psychotropic Drugs, *M. H. Lader* 452

Erratum
Recent advances in the electrophysiological characterization of 5-HT_3 receptors, *John A. Peters, Hilary M. Malone and Jeremy J. Lambert* 452

Author Index 455

Subject Index 459